Alignment Healthcare, Inc. (NASDAQ: ALHC) reported an insider sale by Chief Executive Officer John E. Kao on March 23, 2026. Mr. Kao sold 118,000 shares of common stock for a total of $2,062,439, at a weighted-average price of $17.4783 per share. Individual execution prices on the block ranged from $17.07 to $17.81.
After the transaction, Kao retains direct ownership of 1,784,868 shares and holds an indirect stake of 2,354,641 shares through the JEK Trust, dated February 8, 2021, for which he serves as trustee. The disposition was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that the company states was adopted on November 21, 2025.
The trade occurred as Alignment Healthcare shares were trading at $17.51, giving the company a market valuation of $3.59 billion. The stock has experienced an 11% decline year to date, even as an analysis by InvestingPro places the company on a Most Undervalued list relative to its Fair Value.
Financial metrics cited alongside the trade detail significant top-line momentum. Alignment is reported to have achieved 46% revenue growth, and it carries a financial health score labeled as GOOD with a value of 3.0. An InvestingPro note included with the disclosure indicates that analysts expect the company to be profitable in the current year.
Recent corporate results provided additional context for investor interest. Alignment Healthcare posted strong fourth-quarter performance, with membership expanding by approximately 25% year over year and revenue increasing by about 44.4%. Those outcomes exceeded expectations and prompted Raymond James to reiterate a Strong Buy rating and a $27.00 price target. Piper Sandler likewise maintained an Overweight rating and assigned a $30.00 price target, citing a better-than-expected medical benefit ratio and adjusted EBITDA for the fourth quarter of 2025.
Separately, the company disclosed a secondary offering of 13.2 million shares of common stock by an affiliate of General Atlantic, L.P. The shares were priced at $19.46 apiece and the company will not receive any proceeds from that sale. J.P. Morgan is serving as the underwriter for the transaction, which is expected to close on March 4, 2026, subject to customary closing conditions.
Context and implications
The insider sale was processed under an established 10b5-1 plan, indicating the trade followed a predetermined schedule rather than an ad hoc decision. The size of the sale, at about $2.06 million, represents a portion of Kao's total direct and indirect holdings and takes place amid ongoing company developments, including strong recent operating performance and the General Atlantic affiliate share offering. The market reaction and the companys trajectory are reflected in analyst coverage and valuations noted above.
Data checklist
- Shares sold: 118,000
- Sale date: March 23, 2026
- Total proceeds: $2,062,439
- Weighted-average price: $17.4783; price range: $17.07 to $17.81
- Direct shares held by Kao after sale: 1,784,868
- Indirect shares held via JEK Trust: 2,354,641
- Rule 10b5-1 plan adoption date: November 21, 2025
- Company trading price at time of report: $17.51
- Market valuation cited: $3.59 billion
- Year-to-date decline: 11%
- Reported revenue growth: 46%
- Financial health score: GOOD, 3.0
- Secondary offering: 13.2 million shares by General Atlantic affiliate at $19.46 each; expected close March 4, 2026; J.P. Morgan underwriter